$ENTB has completed pre-clinical research indicating that, by inhibiting NR2F6, cancer stem cells can be converted into normal cells, thus potentially curing the patient of cancer. Additionally, activators of NR2F6 have the potential to provide relief from autoimmune diseases such as arthritis.

They have licensed this associated technology out to Zander Therapeutics, primarily for use by that company’s wholly owned subsidiary, Entest BioMedical Inc, a publicly traded biotechnology company focused on veterinary medicine. Learn more at: http://zandertherapeutics.weebly.com